On-Demand CGT Formulation Webinars

  1. The Next Frontier In mRNA: Modular Manufacturing For Scalable RNA-LNP Therapies 1/29/2025

    Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.

  2. Analytical Solutions To Help Accelerate Bioprocessing Success 11/1/2024

    Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

  3. How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing 5/23/2024

    Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.

  4. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  5. Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles 4/25/2024

    The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

  6. Translation Of RNA Nanomedicines From Design To Clinical 4/14/2022

    mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.

  7. mRNA LNP Scale Up For GMP Vaccine Production 4/14/2022

    Explore an overview of the development and scale-up activities needed to develop high quality lipid nanoparticles and progress this saRNA vaccine to the clinic.

  8. Democratizing RNA Nanotherapeutics 4/14/2022

    This webinar is presented by Dr. John P. Cooke, Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute, Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.

  9. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

  10. Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery 4/14/2022

    Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.